Abstract:// Dennis Ruder 1, 2 , Vassiliki Papadimitrakopoulou 4 , Kazuhiko Shien 2 , Carmen Behrens 4 , Neda Kalhor 5 , Huiqin Chen 6 , Li Shen 3 , J. Jack Lee 6 , Waun Ki Hong 4 , Ximing Tang 2 , Luc Girard 7 , John D. Minna 7 , Lixia Diao 3 , Jing Wang 3 , Barbara Mino 2 , Pamela Villalobos 2 , Jaime Rodriguez-Canales 2 , Nana E. Hanson 2 , James Sun 9 , Vincent Miller 9 , Joel Greenbowe 9 , Garrett Frampton 9 , Roy S. Herbst 8 , Veera Baladandayuthapani 6 , Ignacio I. Wistuba 2 and Julie G. Izzo 2 1 Graduate Program in Human and Molecular Genetics and Cancer Biology, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA 2 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 6 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 7 Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas, USA 8 Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA 9 Foundation Medicine, Inc., Cambridge, Massachusetts, USA Correspondence to: Julie G. Izzo, email: jizzo@mdanderson.org Ignacio I. Wistuba, email: iiwistuba@mdanderson.org Keywords: RICTOR gene abnormalities; KRAS mutation; MAPK pathway; mTORC2; non-small cell lung cancer Received: April 13, 2018 Accepted: September 09, 2018 Published: September 21, 2018 ABSTRACT Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.

Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer.

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy.

Characterization of the Mtor Pathway in Renal Cell Carcinoma and Its Use in Predicting Patient Selection for Agents Targeting This Pathway

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma

Abstract 3515: Pathway Convergent Evolution Underscores Treatment Response to MTOR Inhibitors in Kidney Cancers.

TABLE 3 from Phase I Study of Mtorc1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mtor/akt/pi3k</i> Pathway Alterations and Advanced Solid Malignancies

Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated Mtor Pathway in Renal Cell Carcinomas

Effective Monotherapy Despite Intratumor Heterogeneity: Clonal Convergence Within the PI3K Pathway and Sensitivity to Mtor Inhibitors in Patients with Advanced Renal Cell Carcinoma (RCC).

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Genetic Determinants of Long-Term Response to Rapalog Therapy in Advanced Renal Cell Carcinoma (RCC).

Supplementary Figure 4 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>bap1</i> and <i>setd2</i>: A Report by MSKCC and the KIRC TCGA Research Network

Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the Mtorc1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

Supplementary Tables S1-6 and S8 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

Supplementary Tables S7 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

Peer Review #1 of "prognostic Significance and Tumor-Immune Infiltration of Mtor in Clear Cell Renal Cell Carcinoma (V0.1)"

Supplementary Table 2 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Table 2 from A Diverse Array of Cancer-Associated <i>MTOR</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity